

Skin Disease-Oriented Team

Clinical Research Treatment Flowchart

First Line, Resectable

SWOG 2015
[1cm v 2cm margin](#)
CRC: N. Arechiga
Accrual: 5/30

First Line, Stage 3
Neoadjuvant + Adjuvant

EA6194
[TLR9 agonist+Pembro + Sx vs Pembro + Sx](#)
CRC: E. Palmer-Torrison
Accrual: 2/6

First Line, Metastatic or unresectable
without previous CPI

EA6141
(III or IV)
[Ipi + Nivo + sargramostin vs. Ipi + Nivo](#)
CRC: B. Huynh
Accrual: 4/5

UCI 22-101
(III or IV)
[Nivo + Rela IV vs SubQ](#)
CRC: N. Arechiga
Accrual: 4/12

Second Line

UCI 22-213
[E7386 + Pembro +/- Lenvatinib](#)
PI: Dayyani
CRC: N. Arechiga
Accrual: 0/7

Open

Low Accrual

Pending Activation or Suspended

Consider Broad Phase 1 Studies

<div>HER2 + / ERBB2 amp</div> <div>UCI 20-67 DF1001 (HER2 NK- engager) PI: Valerin CRC: M. Nguyen Accrual: 18/20</div>	<div>NRAS mutant</div> <div>UCI 20-169 <u>Belvarafenib +/- cobimetinib +/- atezolizumab</u> CRC: E. Palmer-Torrison Accrual: 0/5 Waitlist only</div>	<div>UCI 21-40 <i>(Locally Advanced or Metastatic Solid Tumors)</i> <u>DF6002 as a Monotherapy and in Combination w/ nivo</u> Valerin CRC: B. Huynh Accrual: 4/6 Waitlist only</div>	<div>UCI 21-38 First in Human (FIH). LVGN6051 +/- pembro CRC: E. Palmer-Torrison Accrual: 5/8 Waitlist only</div>	<div>UCI 20-110 TAK-981 + Pembro (sumoylation inhibitor) (Tewari) CRC: N. Patel Accrual: 2/5</div>	<div>UCI 22-87 (RMC-6236) <u>Mechanism: TKI</u> Coordinator: Oliver Quines Accrual: 6/20</div>	<div>Open</div> <div>Low Accrual</div> <div>Pending Activation or Suspended</div>
---	--	--	---	---	---	---



Non-treatment Trials

UCI 19-135

DecisionDx-Melanoma Impact on Sentinel Lymph
Node Biopsy Decisions and Clinical Outcomes
(DECIDE)

CRC: Anastasiia R.
Accrual: 64/70

Open

Low Accrual

Pending
Activation
or
Suspended

First Line, Stage 3
Neoadjuvant + Adjuvant

Recurrent

ETCTN 10592
M1774 +/- avelumab

CRC: N. Arechiga
Accrual: 0/6

Open

Low Accrual

Pending
Activation
or
Suspended

First Line

Broad Phase 1 trials

UCI 22-42
TransCon Toll like receptor
(TLR) 7/8 agonist
Coord: Nirali Patel
Accrual: 0/5

UCI 22-87
(RMC-6236)

Mechanism: TKI
Coordinator: Oliver
Quines
Accrual: 6/20

UCI 22-87
(RMC-6236)

Mechanism: TKI
Coordinator: Oliver
Quines
Accrual: 6/20

Open

Low Accrual

Pending
Activation or
Suspended

Closed

January 2024